Biostatistics Support

Gain stronger clarity in communication with the methodical biostatistics CRO services needed for drug development today!

The MMS team are all superstars! You have delivered to timelines throughout, and we really appreciate it. Thank you!
Satisfied Sponsor
Biometrics Division

Expert biostatisticians at MMS hold the trust of leading pharmaceutical and biotechnology Sponsors. Our biostatistics team has an incomparable, industry-educated skill set and end-game experience to provide support in:

  • Sample size calculations,
  • Randomization schedules,
  • Statistical analysis plans (SAP),
  • Data interpretation,
  • Collaborative solution finding on data/analysis related hurdles, and much more.

When Sponsors engage an MMS biostatistician, they are guaranteed clarity in understanding the statistical rationale and excellent communication with all team members, including programmers, data management, data scientists, medical writers, and clinicians. 

The success of a clinical trial depends on the strength and knowledge of the biostatistics lead. When supporting Sponsors with statistical analyses and protocol development for global health authority responses and/or publication support, the biostatisticians at MMS are experienced, attentive, methodical, and intuitive.

What Differentiates MMS From Other CROs?

responsive

MMS is more responsive, taking responsibility for the success of every project with consistent staff and proactive solutions that exceed the expectations of a CRO partner.

adaptable

MMS is more adaptable, knowing your satisfaction and top outcomes are dependent on our ability to remain nimble and make smart decisions based on scientifically-sound data.

focused

MMS is more focused, providing data-centric solutions and innovative technology and processes that help accelerate and de-risk the development and approval of your therapy.

Suggested For You

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth

perspectives

September 30th, 2024

The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry

perspectives

September 24th, 2024

Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry

perspectives

September 11th, 2024

From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

perspectives

September 4th, 2024

Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders

perspectives

August 27th, 2024

Optimizing Oncology Drug Development: FDA Expedited Pathways, Real-Time Review, and Global Programs

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval

perspectives

August 20th, 2024

Clinical Study Protocols: A Comprehensive Guide to Best Practices From A Senior Medical Writer